Q-omics provides the consensus-scored PRDX2P1 profile across patient tissues and cancer cell-line models. PRDX2P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PRDX2P1 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, PRDX2P1 RNA expression shows 11,056 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, COAD, and ACC as cancer lineages where PRDX2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX2P1 survival associations across molecular data types. PRDX2P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX2P1 RNA expression–survival associations across cancer types. High PRDX2P1 expression shows unfavorable associations in BLCA, THYM and DLBC, but favorable associations in HNSC, LUSC and COAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for PRDX2P1 RNA expression.
This table summarizes PRDX2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRDX2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX2P1 shows higher tumor expression in COAD, BLCA and PRAD. The COAD box plot shows higher PRDX2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.712, t-test p < 0.001).
This table shows molecular features associated with PRDX2P1 in patient tissues and cancer cell lines. In patient samples, PRDX2P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
